Keryx appoints interim chairman, CEO

NEW YORK Drug maker Keryx Pharmaceuticals has appointed Michael Tarnok as its interim chairman and CEO, the company announced Thursday.

Tarnok, who has served on Keryx’s board of directors since September 2007, will replace Michael Weiss.

Tarnok spent most of his career working at Pfizer, having joined that company as finance director for U.S. manufacturing in 1989 and serving as SVP finance in its U.S. pharmaceuticals division from 2000 to 2007.